abexinostat

Also known as CRA-024781, PCI-24781

Abexinostat (INN, formerly PCI-24781) is an experimental drug candidate for cancer treatment. It was developed by Pharmacyclics and licensed to Xynomic. , it was in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well.

Research

57 papers

Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study.BMC cancer · 2025
The Bioequivalence of Abexinostat (CRA-024781) Tosylate Tablets (20 mg) in Chinese Healthy Subjects Under Fasting Conditions.Clinical pharmacology in drug development · 2024
Development of an UPLC-MS/MS method for quantitative analysis of abexinostat levels in rat plasma and application of pharmacokinetics.BMC chemistry · 2024
A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.Leukemia & lymphoma · 2024
Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.Oncotarget · 2017

via PubMed

Wikidata facts

Mass: 397.163771

Show 2 more facts

chemical formula: C₂₁H₂₃N₃O₅
canonical SMILES: CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO

Sources (2)

via Wikidata · CC0

~2 min read

Article

4 sections

Contents

Progress
Research
Safety and efficacy
References

{{Chembox | Verifiedfields = changed | verifiedrevid = 486401721 | ImageFile = Abexinostat.svg | ImageClass = skin-invert-image | ImageSize = | IUPACName = 3-[(Dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide | OtherNames = PCI-24781; CRA-024781 | Section1 = | Section2 = | Section3 = | Section5 = }}